Regeneration Biomedical’s Dr. Duma Interviewed On Life Science Success Podcast
PFD Capital Partners is pleased to share a featured video interview of Dr. Christopher Duma, CEO of Regeneration Biomedical, on the highly regarded Life Sciences Success podcast hosted by Dr. Don Davis. In the episode, Dr. Duma provides valuable insight into the limitations of current treatment options for central nervous system (CNS) diseases such as […]
PFD Management Shares Update PFD/iOI’s FIH Implant
PFD/iOI announces it has cleared the final hurdles in order to move ahead with its First-In-Human implant of its RAD/iKnee technology.
PFD Management Shares Q123 Clinical Progress and Update On CassdermaRx
The FDA and HHS release report discussing the need for better care protocols for patients suffering from chronic wound issues. This support PFD’s efforts with CassdermaRx, one of the medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
PFD iOI Announces Update On The iKnee Comfort Study And The Path Forward
PFD/iOrthopedics, Inc. (PFD/iOI) has announced further details on its upcoming iKnee Comfort Study.
PFD iOI Announces Updates On The RAD/iKnee Lab Installation
PFD/iOI has released an update on the installation of its ARBURG Freeformer 300-3X 3D printer into the PFD/iOI RAD iKnee Lab at its Los Angeles facility.
PFD iOI Announces Acquisition of Arburg Freeformer 300-3X For Production Of iKnee
PFD/iOI has announced the purchase of the Arburg Freeformer 300-3X 3D printer to start prototype development and manufacture of its iKnee technology. The printer is to be installed at PFD/iOI’s new clean room lab at its Los Angeles facility.
PFD Management Shares End of Year HHS Public Access Author Manuscript Recognition from CassdermaRx
The FDA and HHS release report discussing the need for better care protocols for patients suffering from chronic wound issues. This support PFD’s efforts with CassdermaRx, one of the medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
PFD Management Shares NKC End-Of-Year Development Report
PFD is proud to share this end-of-year update on Neuro-Kinesis Corporation which is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
PFD Management Opportunity Fund 3001 Press Release November 15, 2022
PFD is proud to share Neuro-Kinesis Corporation’s fourth quarter 2023 update on it Huygens™ Catheter and Proteus™ Robotic Arm Technologies. this end-of-year update on Neuro-Kinesis Corporation is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
PFD/iOI Release Update On Their Resilient Arthroplasty Device (RAD) Technology
PFD is pleased to share this updates on its PFD/iOi venture. This includes information of the latest design enhancements by our engineering team for the Resilient Arthroplasty Device – iKnee. as well as information the finalized prototype design, and the initial Proof of Concept with First In Human implant and the launch of the iKnee Comfort Study.